Compositions comprising methylphenidate-prodrugs, processes of making and using the same
The present technology is directed to d-threo-methylphenidate conjugates and a composition comprising d-threomethylphenidate conjugated to nicotinoyl-L-serine, or salt thereof. The present technology also relates to a composition comprising at least one conjugate of d-methylphenidate having at least two or more chiral centers. The composition is optically active. The present technology additionally relates to oral formulations and pharmaceutical kits comprising at least one d-threo-methylphenidate conjugate. The pharmaceutical kit may comprise a specified amount of individual doses in a package. Each individual dose in the package may contain a pharmaceutically effective amount of a conjugate of d-threo methylphenidate.
1. A method of extending the release of d-methylphenidate in a human or animal subject as compared to the release of d-methylphenidate of an equivalent molar amount of immediate release unconjugated d-methylphenidate, the method comprising orally administering to the human or animal subject a pharmaceutically or therapeutically effective amount of a composition comprising a compound, wherein the compound is a conjugate of d-methylphenidate, having the following chemical formula:
or salt of said compound, wherein oral administration of said pharmaceutically or therapeutically effective amount of the composition is effective to produce an extended release of d-methylphenidate in the subject as compared to the release of d-methylphenidate upon oral administration of an equivalent molar amount of immediate release unconjugated d-methylphenidate.
2. The method of claim 1 , wherein the salt of the compound is a pharmaceutically acceptable salt selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, martrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate, galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate, hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate and combinations thereof.
3. The method of claim 2 , wherein the pharmaceutically acceptable salt of the compound has the following structure:
4. A method for producing both an immediate release and extended release of d-methylphenidate in a human or animal subject as compared to the release of d-methylphenidate of an equivalent molar amount of unconjugated d-methylphenidate, the method comprising orally administering to the human or animal subject a pharmaceutically or therapeutically effective amount of a composition comprising a compound, wherein the compound is a conjugate of d-methylphenidate, having the following chemical formula:
or salt of said compound wherein oral administration of said pharmaceutically or therapeutically effective amount the composition is effective to produce both an immediate release and extended release of d-methylphenidate in the human or animal subject as compared to the release of d-methylphenidate upon oral administration of an equivalent molar amount of unconjugated d-methylphenidate.
5. The method of claim 4 , wherein the pharmaceutically acceptable salt of the compound has the following structure:
6. The method of claim 1 , wherein the pharmaceutically acceptable salt of the compound has the following structure:
and the subject is human.
7. The method of claim 4 , wherein the pharmaceutically acceptable salt of the compound has the following structure:
and the subject is human.